Paul Hudson, Sanofi CEO (AP Images)
A top pick in Paul Hudson's campaign to revive the pipeline at Sanofi blows up in PhIII
One of Paul Hudson’s picks for Sanofi’s pipeline has gone down in defeat in a Phase III trial.
Rilzabrutinib, the number 2 BTK inhibitor plucked …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
